Activation of tumor-specific T cells by dendritic cells expressing the NY-ESO-1 antigen after transfection with the cationic lipophosphoramide KLN5

✍ Scribed by Matthieu Le Gallo; Olivier Toutirais; Tristan Montier; Florian Cabillic; Françoise Bouet; Pascal Delépine; Pierre Lehn; Francine Jotereau; Véronique Catros

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 769 KB
• Volume: 10
• Category: Article
• ISSN: 1099-498X
• DOI: 10.1002/jgm.1188

✦ Synopsis

Abstract

Background

Genetic modification of human monocyte‐derived dendritic cells (DC) with cDNA sequences encoding tumor‐associated antigens (TAA) is a promising strategy for cancer immunotherapy. The present study aimed to develop a nonviral gene transfer method based on the use of the cationic lipophosphoramide reagent, KLN‐5, as an alternative to the commonly used viral vectors.

Methods

First, the efficiency of KLN5 for gene transfection into DC was investigated using the green fluorescent protein (GFP) reporter gene. The highest transfection efficiency/cell viability ratio was determined by flow cytometry. Next, DC were transfected with a plasmid encoding NY‐ESO‐1, a TAA expressed in numerous cancers, according to the transfection protocol previously established with the GFP reporter. Transfected DC were then co‐cultured with a CD8+ NY‐ESO‐1 specific HLA‐A*02.01 T cell clone to control their ability to correctly process and present the corresponding epitope in the HLA‐A*02.01 context. Finally, T cell activation was assessed via flow cytometry‐based detection of interferon‐γ production.

Results

An optimal KLN5/plasmid DNA ratio allowing both significant transgene expression and high viability of DC could be determined. Under the established experimental conditions, antigen processing and presentation of the immunodominant (SLLMWITQC~157–165~) epitope in the HLA‐A*0201 context was demonstrated by activation of the NY‐ESO‐1‐specific CD8+ T cell clone.

Conclusions

KLN5‐based gene transfection into DC allows the efficient induction of TAA presentation and may thus represent a novel attractive nonviral approach for cancer vaccination. Copyright © 2008 John Wiley & Sons, Ltd.